Dr. James T. Sing JR., D.O.
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Medical school
- University of North Texas Hsc, College of Osteopathic Med (1997)
- Years since graduation
- 29
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 420
Licensed in Texas since 1998, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1997Medical school: University of North Texas Hsc, College of Osteopathic Med
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
TX license K5694 (first issued 1998; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baylor Scott & White Medical Center - Temple Temple, TX
Medical groups
- Scott and White Clinic (2,461 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 420
- Services billed
- 626
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 82 | 69 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 65 | 64 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 46 | 46 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 46 | 46 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 44 | 44 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 37 | 37 |
| Insertion of guide wire with dilation of esophagus using a flexible endoscope | 37 | 36 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 25 | 25 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 24 | 23 |
| Established patient office or other outpatient visit, 20-29 minutes | 18 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Omeprazole Other prescribers in Temple, TX | 59 |
| Dicyclomine Hcl Other prescribers in Temple, TX | 31 |
| Mesalamine Other prescribers in Temple, TX | 28 |
| Pantoprazole Sodium Other prescribers in Temple, TX | 24 |
| Viberzi (eluxadoline) | 19 |
| Esomeprazole Magnesium Other prescribers in Temple, TX | 16 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Temple, TX | 14 |
| Creon (lipase/protease/amylase) Other prescribers in Temple, TX | 13 |
| Lubiprostone Other prescribers in Temple, TX | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 5 payments worth $120 in total to this clinician.
| Aimmune Therapeutics, Inc. | $29.03 |
|---|---|
| AbbVie Inc. | $28.03 |
| Janssen Biotech, Inc. | $25.93 |
| Enterra Medical, Inc. | $20.56 |
| Boston Scientific Corporation | $16.60 |
| Food and Beverage | $120 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 1 companies. The companies reported $3,818 in research payments for these studies, mostly to the institutions running them.
- A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
AbbVie Inc. - A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
AbbVie Inc. · Completed · NCT01848561 - A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn Disease (CD)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.